We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Abilify Approved for Adolescent Schizophrenia
Abilify Approved for Adolescent Schizophrenia
November 9, 2007
Bristol-Myers Squibb (BMS) and Otsuka Pharmaceuticals received good news from the FDA as the agency approved their antipsychotic drug Abilify for the treatment of schizophrenia in adolescents ages 13–17.